Measuring bile acids in blood and tumor tissue to help detect and predict treatment response in testicular germ cell tumors
Official title: Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity (TG-BIL)
Run by University Hospital, Clermont-Ferrand · NCT07463508 · Data updated 2026-11-12
This project will measure bile acids and related signals in blood and tumor tissue to see if they can help detect disease and predict chemotherapy response in adult men with testicular germ cell tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 20 (estimated) |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 1 site (Clermont-Ferrand) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | January 1, 2029 |
| Study ends | January 1, 2029 |
| Registry record updated | March 11, 2026 |
| Trial ID | NCT07463508 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult men with a confirmed testicular germ cell tumor before orchiectomy who can give informed consent and are affiliated with the French social security system are eligible.
✕Probably not a fit
Patients with hepatobiliary disease, those treated with cholestyramine, people who have had cholecystectomy or major small-bowel resection, patients with another active cancer, or those already enrolled in a therapeutic clinical trial are excluded and unlikely to benefit from this biomarker work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adult men with a clinical and biological diagnosis of testicular germ cell tumor will provide blood samples and tumor tissue (typically collected before orchiectomy). Investigators will quantify bile acid concentrations and related signaling markers in blood and tissue and link those measurements to tumor histology, disease stage, and chemotherapy response. The study excludes patients with conditions or surgeries that change bile acid metabolism to avoid confounding results. Clinical follow-up data will be used to test whether these markers correlate with prognosis or chemosensitivity.
Why it matters
Potential benefit: If successful, the biomarkers could help identify more aggressive disease earlier and predict which patients are likely to respond to chemotherapy, supporting more personalized treatment decisions.
How similar studies have gone: Using bile acid signaling as a biomarker in testicular cancer is largely exploratory; bile acids have been studied in other cancers and metabolic disorders but evidence for predicting germ cell tumor chemosensitivity is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient, male, with a clinical and biological diagnosis of germ cell tumor of the testis in pre-orchidectomy, at the stage of the disease and any histological subtype of germ cell tumor * Affiliation with a Social Security organization * Able to give informed consent to participate in the research. Exclusion Criteria: * Patient with a hepatobiliary pathology * Patient treated with Colestyramine * Patient who has undergone cholecystectomy or extensive resection of the small intestine * Patient deprived of liberty * Patient under guardianship, curatorship, or legal protection * Patient unable to understand the protocol (language barrier, cognitive difficulties) * Patient with another active cancer * Patient participating in a therapeutic clinical trial * Refusal to participate
Where it's running
-
CHU Clermont-Ferrand
Clermont-Ferrand, France Recruiting
Study contacts
- Study coordinator: Lise LACLAUTRE
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: 0473754963
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using microRNA to improve testicular cancer management
This study is testing if a specific microRNA can help doctors better detect and manage testicular cancer by identifying active tumor cells in patients.
-
miRNA371 blood testing for men with newly diagnosed or prior germ cell tumors
This project will test whether a blood test measuring miRNA371 can detect active or returning germ cell tumors in men with a new or prior diagnosis of testicular germ cell cancer.
-
Safety and tolerability of XmAb541 in patients with advanced solid tumors
This study is testing a new drug called XmAb541 to see if it's safe and how well it works for people with advanced solid tumors like ovarian and endometrial cancer.
-
Home-based follow-up for testicular cancer patients
This study tests if a home-based follow-up for people who have recently finished treatment for testicular cancer can help them feel better and less anxious compared to regular hospital visits.
-
Add Pedmark to cisplatin chemotherapy to prevent hearing loss in men with stage II–III metastatic testicular germ cell tumors
We will test whether adding Pedmark to cisplatin chemotherapy reduces hearing damage in men with stage II–III metastatic testicular germ cell tumors.
-
Comparing in-person and remote monitoring for cancer follow-up
This study is testing whether patients with rare tumors follow their post-treatment care plans better with in-person visits from a doctor or remote check-ins with a nurse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.